We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




‘Smart Patch’ Detects Alzheimer's Using Microneedle Technology

By LabMedica International staff writers
Posted on 19 Jan 2023
Print article
A new diagnostic tool uses skin as a window to the body and brain (Photo courtesy of Swansea University)
A new diagnostic tool uses skin as a window to the body and brain (Photo courtesy of Swansea University)

A new ‘smart patch’ can detect proinflammatory biomarkers of neurodegenerative diseases such as Parkinson's and Alzheimer's by using microneedle technology. The breakthrough in the advancement of transdermal capability could pave the way for the use of ‘smart patches’ to detect certain biomarkers within skin interstitial fluid (ISF) in a “bloodless” manner. The patches are comprised of arrays of tiny needles (microneedles) that are designed to break the skin barrier – in a minimally invasive manner - and monitor clinically significant biomarkers. They can be self-administered for POC diagnosis or at home. The innovation could prove to be a game changer in the field of early neurodegenerative disease detection.

The skin is the largest organ in the body and contains more ISF than the total volume of blood. The fluid is an ultrafiltrate of blood and holds biomarkers that complement other biofluids like sweat, saliva, and urine. It can be sampled in a minimally invasive way and used for testing at the POC as well as in real time using microneedle devices. Dr. Sanjiv Sharma, a leading scientist at Swansea University (Swansea, UK) who had previously developed the world’s first COVID-19 ‘smart patch’, employed microneedle array-based biosensing patches as wearable transdermal sensors to detect the proinflammatory cytokine IL-6. IL-6 is present in the skin ISF with other cytokines and is implicated in several clinical states including neurodegenerative diseases and fatal pneumonia due to SARS-CoV-2.

Dr. Sharma and his collaborators were able to detect IL-6 at concentrations as low as 1 pg/mL in synthetic skin ISF, suggesting its utility for routine POC, bloodless measurements in simpler settings, across the world. The devices developed by the team are scalable, and the resulting sensor has a short measurement time of six minutes, along with high accuracy and low limit of detection. The new diagnostic tool for screening of inflammatory biomarkers in POC testing tunes the skin into a window to the body and vital organs like the brain.

“Biomark ISEP Porto have pioneered applications of molecular imprinted polymers (MIPs) and extended them to different healthcare applications,” said Felismina Moreira from the School of Engineering, Polytechnic Institute, who also collaborated in the research. “Together with Swansea's expertise in transdermal diagnostics we have demonstrated that the MIPs together with the microneedle arrays offers a fantastic platform for the development of point of care devices for bloodless testing. These can be extended to diagnostics for cardiovascular, cancer and neurodegenerative disorders.”

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.